Product Description
a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30502343/)
Mechanisms of Action: M3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Overactive Bladder
Phase 1: Healthy Volunteers|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05812417 |
DA8010_RI_I | P1 |
Completed |
Kidney Diseases |
2024-06-07 |
23% |
2024-06-28 |
Primary Completion Date|Primary Endpoints|Start Date |
NCT05282069 |
DA8010_OAB_III | P3 |
Completed |
Overactive Bladder |
2023-11-01 |
11% |
2024-06-28 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05991401 |
DA8010_DICR_I | P1 |
Completed |
Healthy Volunteers |
2023-11-06 |
23% |
2024-01-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05992428 |
DA8010_DIPM_I | P1 |
Completed |
Healthy Volunteers |
2023-11-07 |
23% |
2024-01-26 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |